Primary osseous tumors of the orbit.

IF 3.4 3区医学 Q1 PATHOLOGY

Virchows Archiv Pub Date : 2024-11-12 DOI:10.1007/s00428-024-03975-6

Mariel Bedell, Rana Naous

引用次数: 0

Abstract

This review article focuses on the various primary osseous tumors of the orbit. Due to overlapping clinical, radiologic, and histologic features, differentiating these entities can pose significant challenges diagnostically. In this review, emphasis is placed on key distinguishing clinical, morphologic, immunophenotypic, and molecular characteristics. Also described are important prognostic details, recurrence risks, and the gold standard treatment methods for each entity. Relevant genetic syndrome associations are additionally covered. Orbital bone entities discussed include osteoma, osteoid osteoma, osteoblastoma, ossifying fibroma, fibrous dysplasia, aneurysmal bone cyst, osteosarcoma, Ewing sarcoma, and mesenchymal chondrosarcoma.

查看原文本刊更多论文

眼眶原发性骨肿瘤。

这篇综述文章的重点是眼眶的各种原发性骨肿瘤。由于临床、放射学和组织学特征的重叠，区分这些实体可能会给诊断带来巨大挑战。在这篇综述中，重点放在关键的临床、形态、免疫表型和分子特征的区分上。此外，还介绍了每种实体的重要预后细节、复发风险和金标准治疗方法。此外，还涉及相关遗传综合征的关联。讨论的眼眶骨实体包括骨瘤、类骨瘤、成骨细胞瘤、骨化性纤维瘤、纤维发育不良、动脉瘤性骨囊肿、骨肉瘤、尤文肉瘤和间质软骨肉瘤。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Virchows Archiv 医学-病理学

CiteScore

7.40

自引率

2.90%

发文量

204

审稿时长

4-8 weeks

期刊介绍： Manuscripts of original studies reinforcing the evidence base of modern diagnostic pathology, using immunocytochemical, molecular and ultrastructural techniques, will be welcomed. In addition, papers on critical evaluation of diagnostic criteria but also broadsheets and guidelines with a solid evidence base will be considered. Consideration will also be given to reports of work in other fields relevant to the understanding of human pathology as well as manuscripts on the application of new methods and techniques in pathology. Submission of purely experimental articles is discouraged but manuscripts on experimental work applicable to diagnostic pathology are welcomed. Biomarker studies are welcomed but need to abide by strict rules (e.g. REMARK) of adequate sample size and relevant marker choice. Single marker studies on limited patient series without validated application will as a rule not be considered. Case reports will only be considered when they provide substantial new information with an impact on understanding disease or diagnostic practice.